141 related articles for article (PubMed ID: 21546834)
1. Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries.
Achhra AC; Phanuphak P; Amin J
Curr Opin HIV AIDS; 2011 Jul; 6(4):258-65. PubMed ID: 21546834
[TBL] [Abstract][Full Text] [Related]
2. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
3. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
4. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
[TBL] [Abstract][Full Text] [Related]
5. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
6. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
7. Early antiretroviral therapy: the role of cohorts.
Sabin CA
Curr Opin HIV AIDS; 2009 May; 4(3):200-5. PubMed ID: 19532051
[TBL] [Abstract][Full Text] [Related]
8. Early versus deferred antiretroviral therapy in children in low-income and middle-income countries.
Puthanakit T; Bunupuradah T
Curr Opin HIV AIDS; 2010 Jan; 5(1):12-7. PubMed ID: 20046143
[TBL] [Abstract][Full Text] [Related]
9. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
[TBL] [Abstract][Full Text] [Related]
10. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
11. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
12. When and why to start antiretroviral therapy?
Gatell JM
J Antimicrob Chemother; 2010 Mar; 65(3):383-5. PubMed ID: 20071369
[TBL] [Abstract][Full Text] [Related]
13. Improvements in antiretroviral therapy outcomes over calendar time.
Boyd MA
Curr Opin HIV AIDS; 2009 May; 4(3):194-9. PubMed ID: 19532050
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
[TBL] [Abstract][Full Text] [Related]
15. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment.
Zhang S; van Sighem A; Gras L; Reiss P; Smit C; Kroon F; Jurriaans S; Prins J; Lange J; de Wolf F
Antivir Ther; 2010; 15(4):555-62. PubMed ID: 20587848
[TBL] [Abstract][Full Text] [Related]
17. Modeling CD4+ cell count increase over a six-year period in HIV-1-infected patients on highly active antiretroviral therapy in Senegal.
De Beaudrap P; Etard JF; Diouf A; Ndiaye I; Guèye NF; Guèye PM; Sow PS; Mboup S; Ndoye I; Ecochard R; Eric D;
Am J Trop Med Hyg; 2009 Jun; 80(6):1047-53. PubMed ID: 19478274
[TBL] [Abstract][Full Text] [Related]
18. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
[TBL] [Abstract][Full Text] [Related]
19. Current and future management of treatment failure in low- and middle-income countries.
Boyd MA
Curr Opin HIV AIDS; 2010 Jan; 5(1):83-9. PubMed ID: 20046152
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
Fischl MA
AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]